Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

Inflammatory bowel disease (IBD) presents with disabling symptoms and may lead to
insufficient growth and late pubertal development in cases of disease onset during …

Background Lack of evidence-based outcomes data leads to uncertainty in developing
treatment regimens in children who are newly diagnosed with ulcerative colitis. We …

Objectives: The aim of the study was to review the evidence regarding the clinical use and
value of fecal calprotectin (FC) measurements in different gastrointestinal disorders in …

Objective: To systematically analyze the supporting evidence, drug information, and the type
of off-label drug use in recommendations on off-label drug use in pediatric guidelines …

Objective: To compile and synthesize the available literature describing medical cannabis
use across various disease states. Data Sources: PubMed, EBSCO, and Google Scholar …

Corticosteroids are the mainstay of therapy for many pediatric disorders and sometimes are
life-saving. Both endogenous and synthetic derivatives diffuse across the cell membrane …

Objectives: Colectomy rates following acute severe ulcerative colitis have plateaued around
20% despite intravenous corticosteroid and intensified anti-tumor necrosis factor (TNF) …

In the course of inflammatory bowel disease (IBD) malabsorption may lead to a vitamin D
deficiency and calcium–phosphate misbalance. However, the reports on the vitamin D status …

Ulcerative colitis (UC) has become a worldwide public health problem, and the prevalence
of the disease among children has been increasing. The pathogenesis of UC has not been …